Molecular Templates (MTEM) Stock Forecast, Price & News

Molecular Templates (NASDAQ:MTEM) Frequently Asked Questions

Is Molecular Templates a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Molecular Templates in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Molecular Templates stock.
View analyst ratings for Molecular Templates or view top-rated stocks.

Are investors shorting Molecular Templates?

Molecular Templates saw a increase in short interest in April. As of April 30th, there was short interest totaling 1,410,000 shares, an increase of 24.8% from the April 15th total of 1,130,000 shares. Based on an average trading volume of 192,600 shares, the days-to-cover ratio is currently 7.3 days. Currently, 3.4% of the shares of the stock are sold short.
View Molecular Templates' Short Interest.

When is Molecular Templates' next earnings date?

Molecular Templates is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Molecular Templates.

How were Molecular Templates' earnings last quarter?

Molecular Templates, Inc. (NASDAQ:MTEM) posted its earnings results on Thursday, May, 12th. The biotechnology company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.04. The biotechnology company had revenue of $8.49 million for the quarter, compared to analyst estimates of $6.88 million. Molecular Templates had a negative net margin of 177.06% and a negative trailing twelve-month return on equity of 110.16%.
View Molecular Templates' earnings history.

When did Molecular Templates' stock split? How did Molecular Templates' stock split work?

Molecular Templates's stock reverse split on Wednesday, August 2nd 2017. The 1-11 reverse split was announced on Tuesday, August 1st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 1st 2017. An investor that had 100 shares of Molecular Templates stock prior to the reverse split would have 9 shares after the split.

What price target have analysts set for MTEM?

1 equities research analysts have issued 1 year target prices for Molecular Templates' stock. Their forecasts range from $4.50 to $9.00. On average, they expect Molecular Templates' stock price to reach $6.75 in the next year. This suggests a possible upside of 568.3% from the stock's current price.
View analysts' price targets for Molecular Templates or view top-rated stocks among Wall Street analysts.

Who are Molecular Templates' key executives?

Molecular Templates' management team includes the following people:

• Dr. Eric E. Poma Ph.D., CEO, Chief Scientific Officer & Director (Age 50, Pay $839.67k)
• Ms. Jason S Kim, Pres & COO (Age 47, Pay $600.41k) (LinkedIn Profile)
• Dr. Roger J. Waltzman M.B.A., M.D., Chief Medical Officer (Age 54, Pay $594.17k)
• Mr. Sean McLennan, Sr. VP of Fin., Controller, Interim Principal Accounting Officer, Interim CFO & Treasurer (Age 51)
• Ms. Megan C. Filoon, Gen. Counsel & Sec.
• Mr. Kurt Elster, Exec. VP of Corp. Devel. (Age 55)
• Dr. Jack Higgins Ph.D., Exec. VP of Operations & Head of Manufacturing (Age 42)
• Dr. Erin Willert Ph.D., Exec. VP of R&D (Age 40)
• Dr. Jen-Sing Liu Ph.D., Exec. VP of Manufacturing (Age 59)
• Dr. Nenad Sarapa M.D., M.S., Sr. VP of Clinical Devel.

Who are some of Molecular Templates' key competitors?

Some companies that are related to Molecular Templates include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), United Therapeutics (UTHR), Repligen (RGEN), Neurocrine Biosciences (NBIX), Halozyme Therapeutics (HALO) and Exelixis (EXEL).
View all of MTEM's competitors.

What other stocks do shareholders of Molecular Templates own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Molecular Templates investors own include ZIOPHARM Oncology (ZIOP), Novavax (NVAX), Gilead Sciences (GILD), TG Therapeutics (TGTX), CEL-SCI (CVM), Pfizer (PFE), Synergy Pharmaceuticals (SGYP), Amarin (AMRN), Corbus Pharmaceuticals (CRBP) and Exelixis (EXEL).

What is Molecular Templates' stock symbol?

Molecular Templates trades on the NASDAQ under the ticker symbol "MTEM."

Who are Molecular Templates' major shareholders?

Molecular Templates' stock is owned by many different institutional and retail investors. Top institutional investors include Bellevue Group AG (19.67%), BlackRock Inc. (5.03%), Vanguard Group Inc. (4.63%), Frazier Life Sciences Management L.P. (2.44%), State Street Corp (1.14%) and Russell Investments Group Ltd. (0.81%). Company insiders that own Molecular Templates stock include Jason S Kim, Kevin M Lalande, Longitude Capital Partners Iii and Target N V Biotech.
View institutional ownership trends for Molecular Templates.

Which institutional investors are selling Molecular Templates stock?

MTEM stock was sold by a variety of institutional investors in the last quarter, including Parkman Healthcare Partners LLC, Northern Trust Corp, Renaissance Technologies LLC, BlackRock Inc., Goldman Sachs Group Inc., UBS Group AG, Vanguard Group Inc., and Dimensional Fund Advisors LP.
View insider buying and selling activity for Molecular Templates or view top insider-selling stocks.

Which institutional investors are buying Molecular Templates stock?

MTEM stock was purchased by a variety of institutional investors in the last quarter, including Frazier Life Sciences Management L.P., Bellevue Group AG, Russell Investments Group Ltd., Endurant Capital Management LP, State Street Corp, ClariVest Asset Management LLC, Connor Clark & Lunn Investment Management Ltd., and Oppenheimer & Co. Inc..
View insider buying and selling activity for Molecular Templates or or view top insider-buying stocks.

How do I buy shares of Molecular Templates?

Shares of MTEM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Molecular Templates' stock price today?

One share of MTEM stock can currently be purchased for approximately $1.01.

How much money does Molecular Templates make?

Molecular Templates has a market capitalization of $56.90 million and generates $38.70 million in revenue each year. The biotechnology company earns $-83.01 million in net income (profit) each year or ($1.38) on an earnings per share basis.

How many employees does Molecular Templates have?

Molecular Templates employs 261 workers across the globe.

When was Molecular Templates founded?

Molecular Templates was founded in 2009.

What is Molecular Templates' official website?

The official website for Molecular Templates is www.mtem.com.

How can I contact Molecular Templates?

Molecular Templates' mailing address is 9301 AMBERGLEN BLVD. SUITE 100, AUSTIN TX, 78729. The biotechnology company can be reached via phone at (512) 869-1555, via email at [email protected], or via fax at 650-474-2529.